Non-invasive fetal RhD genotyping could be introduced in Australia to identify which RhD negative women are carrying RhD positive babies and therefore require antenatal anti-D prophylaxis therapy. According to a recent cost-effectiveness analysis, the cost of implementing such a targeted anti-D program would be largely offset by lower use of valuable anti-D products and related ...
Conservation of anti-D products possible with fetal RhD testing
By Mardi Chapman
1 Feb 2018